A
Alcista
Alcista · 25%CYCN
$4.06
Precio del escenario
$23.520
-4.925 (-20.94%)Al cierre
Loading chart…
- Máximo
- 26.880
- Apertura
- 26.040
- Precio medio ponderado por volumen
- 23.38
- Volumen
- 62.49K
- Capitalización
- 5.37M
- Mínimo
- 19.740
- Importe
- 1.46M
- EV/EBITDA, TTM
- 0.00
Korsana Biosciences, Inc., formerly Cyclerion Therapeutics, Inc., is a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases. The Company's lead program, KRSA-028, is a next-generation shuttle antibody targeting amyloid beta for the treatment of Alzheimer’s disease. KRSA-028 leverages Therapeutic Targeting (THETA), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, it is advancing a pipeline of innovative therapies for neurodegenerative diseases.
Análisis de IA of Cyclerion Therapeutics Inc (CYCN)
ComprarCyclerion Therapeutics Inc (CYCN) is currently a good buy due to its recent merger announcement with Korsana Biosciences, which has significantly boosted investor sentiment and resulted in a stock price increase of over 150%. The stock has shown a year-to-date change of +217.16%, indicating strong momentum. However, the main risk is its negative earnings, with a recent EPS of -0.41 and a forward P/E ratio of 0, suggesting uncertainty in profitability moving forward.
Métricas de valoración
El PER previsto actual de Cyclerion Therapeutics Inc (CYCN) es 0.00, frente a su media de 5 años de -0.34.
Escenarios de precio de Alphio AI para CYCN
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
7.005-04PRnewswireInvestor Rights Law Firm Investigates Multiple Companies for Potential Violations
8.504-09PRnewswireInvestor Rights Law Firm Investigates Multiple Companies for Potential Violations
8.504-09GlobenewswireInvestigation Alerts for Multiple Company Mergers
7.004-07GlobenewswireInvestor Rights Law Firm Investigates Multiple Companies for Potential Violations
7.004-03GlobenewswireInvestor Rights Law Firm Investigates Multiple Companies for Potential Violations
Preguntas frecuentes sobre CYCN, respondidas por Alphio AI
Korsana Biosciences, Inc., formerly Cyclerion Therapeutics, Inc., is a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases. The Company's lead program, KRSA-028, is a next-generation shuttle antibody targeting amyloid beta for the treatment of Alzheimer’s disease. KRSA-028 leverages Therapeutic Targeting (THETA), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, it is advancing a pipeline of innovative therapies for neurodegenerative diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Cyclerion Therapeutics Inc (CYCN) is currently a good buy due to its recent merger announcement with Korsana Biosciences, which has significantly boosted investor sentiment and resulted in a stock price increase of over 150%. The stock has shown a year-to-date change of +217.16%, indicating strong momentum. However, the main risk is its negative earnings, with a recent EPS of -0.41 and a forward P/E ratio of 0, suggesting uncertainty in profitability moving forward.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- Money Market Funds vs High-Yield Savings vs T-Bills: Where to Park Cash as the Fed HikesMoney market funds, high-yield savings or T-bills? Compare November 2026 yields, taxes, FDIC rules and liquidity as the Fed hikes, and build a smart cash plan.
- Homebuilder Stocks With Mortgage Rates Above 7%: An Investor's Guide for Late 2026Homebuilder stocks face 7% mortgage rates and a 16-year low in home sales. See what D.R. Horton, Lennar and Pulte earnings show and how to invest in 2026.
- Bitcoin Bear Market 2026: Why BTC Fell Below $70K and How Investors Can Manage Crypto RiskBitcoin is about 45% below its $126K peak as Fed hikes, 5% yields and ETF outflows bite. See how the 2026 bear market compares and how to manage crypto risk.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.